AstraZeneca begins antisense medicine clinical trial for dyslipidemia
ION449 is designed to lower blood cholesterol levels by targeting PCSK9. Credit: Belova59 from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
